Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano

This first multicenter, multinational, latinamerican, open study was designed to evaluate efficacy and safety of nimodipine in patients with Primary Degenerative Dementia-Alzheimer type (PDD-AD) and Multiinfarct Dementia (MID). The study ran for 12 weeks, and at baseline and every 4 weeks, the patients were evaluated with a battery of cognitive tests: Mini Mental State Examination (MMSE) and Trail Making Test (TMT-A), and also behavioral-functional scales like SCAG and RAGS-E. There was a significant difference in the majority of the test performances among baseline and at the end of the study in both groups. This significant improvement was also noticed independently by the caregivers assessed by the RAGS-E scale. The alleviation of behavioral symptoms in both groups, including anxiety, irritability, hostility, and paranoia, particularly in PDD-AD patients, makes us suggest that nimodipine could be used as an effective and safe drug to alleviate cognitive and behavioral symptoms in the two more common causes of dementia world wide.